<DOC>
	<DOC>NCT00174408</DOC>
	<brief_summary>The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)</brief_summary>
	<brief_title>Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age</brief_title>
	<detailed_description />
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Birth length below 2 SD Height at start below 2 Sd Any endocrine or chronic disease Any known syndrome with short stature</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>